Manufacturers announce positive data for selinexor for multiple myeloma in Phase III trial

In the BOSTON study, selinexor (a CRM1 nuclear export inhibitor currently under investigation), in combination with bortezomib and dexamethasone had an increased progression free survival vs bortezomib and dexamethasone alone (13.93 vs 9.46 months).

Source:

Cancer